- Trials with a EudraCT protocol (2,051)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
2,051 result(s) found for: Inflammatory Diseases.
Displaying page 1 of 103.
EudraCT Number: 2010-023254-36 | Sponsor Protocol Number: GUMPID002 | Start Date*: 2011-06-22 | |||||||||||
Sponsor Name:Brighton and Sussex University Hospitals NHS Trust | |||||||||||||
Full Title: Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)? | |||||||||||||
Medical condition: Pelvic Inflammatory Disease (PID) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001602-24 | Sponsor Protocol Number: Th.B-1(2007):BTX(CP/CPPS) | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Department of Urology and Pediatric Urology - Justus-Liebig-University Giessen | |||||||||||||
Full Title: Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) | |||||||||||||
Medical condition: chronic prostatitis / chronic pelvic pain syndrom | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003942-28 | Sponsor Protocol Number: MLN0002-3023 | Start Date*: 2016-05-29 | |||||||||||||||||||||
Sponsor Name:Takeda Development Centre Europe, Ltd. | |||||||||||||||||||||||
Full Title: Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying... | |||||||||||||||||||||||
Medical condition: Primary Sclerosing Cholangitis (PSC) Inflammatory Bowel Disease (IBD) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) BE (Prematurely Ended) GB (Completed) HU (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) PL (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-000916-25 | Sponsor Protocol Number: GIU-5-ASA1.2 MMx-01-03 | Start Date*: 2004-09-28 | |||||||||||
Sponsor Name:GIULIANI | |||||||||||||
Full Title: A PHASE III PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUPS, STUDY, TO ASSESS THE EFFECT OF 5-ASA MMx 1.2 g Tablets IN MAINTENANCE OF REMISSION OF LEFT-SIDED ULCERATIVE COLITIS | |||||||||||||
Medical condition: TREATMENT OF ULCERATIVE COLITIS IN ACTIVE PHASE AND IN THE MAINTENANCE OF CLINICAL REMISSION | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002968-49 | Sponsor Protocol Number: BN43118 | Start Date*: 2022-06-24 | |||||||||||||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PATIENTS WITH GUILLAIN-BARRÉ S... | |||||||||||||||||||||||
Medical condition: Guillain-Barré syndrome (GBS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005414-20 | Sponsor Protocol Number: 14/05 | Start Date*: 2006-03-06 | |||||||||||
Sponsor Name:ISTITUTO PER L INFANZIA BURLO GAROFOLO | |||||||||||||
Full Title: Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. | |||||||||||||
Medical condition: Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004162-13 | Sponsor Protocol Number: SAE-13/IBD | Start Date*: 2007-02-27 | |||||||||||
Sponsor Name:Charité Universitätsmedizin, Campus Charité Mitte | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease | |||||||||||||
Medical condition: Active inflammatory bowel disease, i.e. either left-sided ulcerative colitis or Crohn´s Disease (Colon) with signs of inflammation within 40 cm ab ano. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005034-36 | Sponsor Protocol Number: CIDPRIT | Start Date*: 2018-05-22 | |||||||||||||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||||||||||||
Full Title: An Italian database-based randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | |||||||||||||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004392-12 | Sponsor Protocol Number: CIDP04 | Start Date*: 2019-11-20 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) BE (Completed) ES (Restarted) NL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001347-31 | Sponsor Protocol Number: RF-2016-02361887 | Start Date*: 2018-07-30 | ||||||||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | ||||||||||||||||||
Full Title: Anti-nerve reactivity as predictor of response to immune therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A proof of concept study with rituximab in patie... | ||||||||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000228-33 | Sponsor Protocol Number: GN12NE462 | Start Date*: 2013-11-07 | |||||||||||
Sponsor Name:NHS Greater Glasgow & Clyde [...] | |||||||||||||
Full Title: Inhibition of complement activation (eculizumab®) in Guillain-Barré Syndrome study | |||||||||||||
Medical condition: Guillain-Barré Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001136-76 | Sponsor Protocol Number: KB034Emendamenton°2 | Start Date*: 2007-07-09 | |||||||||||
Sponsor Name:KEDRION | |||||||||||||
Full Title: Double blind Randomized Controlled trial of prolonged treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)with high dose intravenous immunoglobulins (IVIg) or intravenous m... | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002492-95 | Sponsor Protocol Number: CCJM112X2203 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, subject and investigator blinded, placebo controlled, multi-center study in parallel groups to assess the efficacy and safety of CJM112 in patients with moderate to severe inflammator... | |||||||||||||
Medical condition: Moderate to Severe Inflammatory Acne | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010921-38 | Sponsor Protocol Number: MDL_2009_27155 | Start Date*: 2009-09-08 | |||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||
Full Title: Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis: A Double-blind, Randomized Placebo-controlled Pilot Study | |||||||||||||
Medical condition: Ulcerative Colitis and the risk of developing colorectal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002438-34 | Sponsor Protocol Number: FAM1 | Start Date*: 2020-08-19 | |||||||||||
Sponsor Name:Department of Neurology, Odense University Hospital | |||||||||||||
Full Title: Fampridine for treatment of residual neurological deficits in patients treated with immunoglobulins for chronic inflammatory demyelinating polyneuropathy | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005558-31 | Sponsor Protocol Number: I10E-1306 | Start Date*: 2015-01-08 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM study I1... | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005557-73 | Sponsor Protocol Number: I10E-1302 | Start Date*: 2014-10-21 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005280-24 | Sponsor Protocol Number: CFTY720I2201 | Start Date*: 2012-10-08 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients ... | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) DE (Prematurely Ended) ES (Completed) GB (Prematurely Ended) IT (Completed) GR (Completed) PL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001714-38 | Sponsor Protocol Number: COVID-RESCAP | Start Date*: 2021-03-04 | |||||||||||
Sponsor Name:Red Cross Hospital Beverwijk | |||||||||||||
Full Title: Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19) | |||||||||||||
Medical condition: COVID 19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024454-10 | Sponsor Protocol Number: 1200.89 | Start Date*: 2011-07-21 | |||||||||||
Sponsor Name:Boehringer Ingelheim | |||||||||||||
Full Title: An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer | |||||||||||||
Medical condition: Locally advanced or metastic Inflammatory Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.